Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.37 |
| ▸ | DHCR7 | Q9UBM7 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | WNT1 | P04628 | 1/20 | 0.30 |
| ▸ | GSK3B | P49841 | 1/20 | 0.30 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24838820 | 0.84 | HRH3 (0.40) | KDM1AHRH3 | |
| SCHEMBL21421777 | 0.78 | SLC6A2 (0.33) | SLC6A2SLC6A4SLC6A3POLB | |
| SCHEMBL24865954 | 0.78 | KMT2A (0.42) | HRH3POLB | |
| SCHEMBL24700242 | 0.77 | NCF1 (0.42) | KDM1AHRH3DHCR7POLB | |
| SCHEMBL27051233 | 0.77 | KDM1A (0.40) | KDM1AHRH3CYP3A4WNT1GSK3B | |
| SCHEMBL19268062 | 0.77 | OPRM1 (0.33) | HRH3DHCR7POLB | |
| SCHEMBL15354330 | 0.76 | KDM1A (0.38) | KDM1AGSK3B | |
| SCHEMBL9911333 | 0.76 | CARM1 (0.47) | KDM1AHRH3POLB | |
| SCHEMBL23919071 | 0.75 | KDM1A (0.39) | KDM1AHRH3CYP3A4WNT1GSK3B | |
| SCHEMBL21421678 | 0.75 | KDM1A (0.39) | KDM1AHRH3CYP3A4WNT1GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230173078-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230173078-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCA2, SMARCC2 | KDM1A 91/4885HRH3 3548/4885DHCR7 587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.